ArticleTransactions of the Royal Society of Tropical Medicine and Hygiene2021
Medicine donation programmes supporting the global drive to end the burden of neglected tropical diseases.
Article in Transactions of the Royal Society of Tropical Medicine and Hygiene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Pharmacological therapies for neglected tropical diseases: a systematic review and evidence gap mapping.Revista da Sociedade Brasileira de Medicina Tropical · 2026Pooled it
- Implications of global health funding patterns for implementation of a novel soil-transmitted helminth and lymphatic filariasis medicine: Ivermectin/albendazole fixed-dose combination.PLoS neglected tropical diseases · 2026Review
- The pharmaceutical industry's multifaceted role in neglected tropical disease control: from market failure to global health innovation.Tropical medicine and health · 2026Review
- Nursing Diagnoses and Interventions in the Field of Action for Patients Undergoing Renal Replacement Therapy: A Scoping Review.Nursing open · 2025Article
- The impact of schistosomiasis on the Global Disease Burden: a systematic analysis based on the 2021 Global Burden of Disease study.Parasite (Paris, France) · 2025Article
- Article
- A positive consequence of the COVID-19 pandemic: how the counterfactual experience of school closures is accelerating a multisectoral response to the treatment of neglected tropical diseases.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023Review
- China's innovation and research contribution to combating neglected diseases: a secondary analysis of China's public research data.Global health research and policy · 2023Article
- A pan-serotype antiviral to prevent and treat dengue: A journey from discovery to clinical development driven by public-private partnerships.Antiviral research · 2023Review
- Leveraging resources and the impact of neglected tropical disease elimination programmes: getting (much) more than what you pay for.International health · 2022Article
- Reduction in DALYs lost due to soil-transmitted helminthiases and schistosomiasis from 2000 to 2019 is parallel to the increase in coverage of the global control programmes.PLoS neglected tropical diseases · 2022Article
- Scientometric analysis of research on trachoma in Brazil, 2000-2020.Revista de saude publica · 2022Article
- Challenges and Tools for In VitroPathogens (Basel, Switzerland) · 2021Review
- Improving timeliness in the neglected tropical diseases preventive chemotherapy donation supply chain through information sharing: A retrospective empirical analysis.PLoS neglected tropical diseases · 2021Article
- Control programs for strongyloidiasis in areas of high endemicity: an economic analysis of different approaches.Infectious diseases of poverty · 2021Article
- Towards global control of parasitic diseases in the Covid-19 era: One Health and the future of multisectoral global health governance.Advances in parasitology · 2021Article
- Setting the stage for a Global Programme to Eliminate Lymphatic Filariasis: the first 125 years (1875-2000).International health · 2020Review
- The role of medicine donations in the global programme for the elimination of lymphatic filariasis.International health · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
19 authors at 15 institutions in 9 countries.
Funding
Abstract
Neglected tropical diseases (NTDs) are targeted for global control or elimination. Recognising that the populations most in need of medicines to target NTDs are those least able to support and sustain them financially, the pharmaceutical industry created mechanisms for donating medicines and expertise to affected countries through partnerships with the WHO, development agencies, non-governmental organisations and philanthropic donors. In the last 30 y, companies have established programmes to donate 17 different medicines to overcome the burden of NTDs. Billions of tablets, capsules, intravenous and oral solutions have been donated, along with the manufacturing, supply chains and research necessary to support these efforts. Industry engagement has stimulated other donors to support NTDs with funds and oversight so that the 'heath benefit' return on investment in these programmes is truly a 'best value in public health'. Many current donations are 'open-ended', promising support as long as necessary to achieve defined health targets. Extraordinary global health advances have been made in filariasis, onchocerciasis, trachoma, trypanosomiasis, leishmaniasis, schistosomiasis, intestinal parasites and others; and these advances are taking place in the context of strengthening health systems and meeting the global development goals espoused by the WHO. The pharmaceutical manufacturers, already strong collaborators in initiating or supporting these disease-targeted programmes, have committed to continuing their partnership roles in striving to meet the targets of the WHO's new NTD roadmap to 2030.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.